NCT03235869

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

A Single Arm Pilot Study of Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, single stage pilot study of radiation therapy plus durvalumab for tumor-stage cutaneous T-cell lymphoma (CTCL).

Conditions

• Cutaneous T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Durvalumab	Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
RADIATION	Radiation Therapy	Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)

Timeline

• Start date: 2018-03-01
• Primary completion: 2023-03-01
• Completion: 2023-03-01
• First posted: 2017-08-01
• Last updated: 2018-03-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study